Another study reported that FOXA1 led to suppressed IL6 expression by disrupting the binding of NFκB to the IL-6 promoter and thus concluded that reduced FOXA1 expression leads to cancer stem cell like properties in tamoxifen resistant cells through the preferential binding of NFκB to the IL-6 promoter and upregulating IL-6 expression (349). The gene discussed is FOXA1; the disease is cancer.